ALSUntangled #81: Pyridostigmine (mestinon^®)

Area of Science:

• Neurology
• Neuroscience
• Pharmacology

Background:

• Neuromuscular junction dysfunction is an early feature of Amyotrophic Lateral Sclerosis (ALS).
• Pyridostigmine enhances acetylcholine availability, potentially improving neuromuscular transmission in ALS.
• The role of altered neuromuscular transmission in ALS progression remains uncertain.

Purpose of the Study:

• To evaluate the potential of pyridostigmine in slowing ALS progression.
• To assess the mechanistic plausibility of pyridostigmine's efficacy in ALS.
• To review existing clinical evidence for anticholinesterase agents in ALS.

Main Methods:

• Review of preclinical findings on neuromuscular junction dysfunction in ALS.
• Analysis of pyridostigmine's proposed mechanisms of action in ALS.
• Examination of clinical trial data for pyridostigmine and similar agents in ALS patients.

Main Results:

• Pyridostigmine lacks plausible mechanisms to modify ALS pathophysiology beyond transient neuromuscular transmission enhancement.
• Patients with ALS (PALS) positive for acetylcholine receptor autoantibodies without myasthenia gravis symptoms are unlikely to benefit.
• Clinical trials involving similar anticholinesterase agents did not demonstrate a slowing of ALS progression.

Conclusions:

• Pyridostigmine is not supported for use in slowing ALS progression due to lack of mechanistic rationale and proven efficacy.
• Common side effects include muscarinic cholinergic symptoms, particularly gastrointestinal issues.
• Further clinical investigation into pyridostigmine for ALS is not warranted based on current evidence.